Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press125810.17650/1726-9776-2007-0-2-34-41DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряOrgan-preserving treatment using neoadjuvant chemotherapy during intravesical immunotherapy with roncoleukin (interleukin-2) for invasive bladder carcinomaОрганосохраняющее лечение с использованием неоадъювантной химиотерапии на фоне внутрипузырной иммунотерапии ронколейкином (интерлейкин-2) при инвазивном раке мочевого пузыряKrasnyiS. A.КрасныйС. А.
Belarus

Minsk

Минск

N.N. Alexandrov Research Institute of Oncology and Medical RadiologyНИИ онкологии и медицинской радиологии им. Н.Н. Александрова300620073234412702202027022020https://oncourology.abvpress.ru/oncur/article/view/1258

The results of a prospective randomized study of the efficacy of neoadjuvant chemoimmunotherapy with intravesical roncoleukin (interleukin- 2) versus the standard M-VAC chemotherapy regimen are analyzed. The study protocol included 60 patients. Additional intravesical administration of roncoleukin failed to affect the frequency and severity of the toxic effects of multidrug therapy. The immediate and long-term results of the proposed regimen were better than those of the standard one. Complete regressions were 53.3±9.1 and 26.7±8.1, respectively (p = 0.049; Mann—Whitney U-test). Organ-preserving surgery was made in 24 (80.0%) study-group patients and in 16 (53.3%) control ones; the difference being significant (p = 0.03, χ2). In the study group, cumulative survival was significantly higher than that in the control group (p = 0.02, log-rank-test). In the groups, overall 5-year survival was 81.4±7.6 and 46.5±12.5%, respectively.

The results of a prospective randomized study of the efficacy of neoadjuvant chemoimmunotherapy with intravesical roncoleukin (interleukin- 2) versus the standard M-VAC chemotherapy regimen are analyzed. The study protocol included 60 patients. Additional intravesical administration of roncoleukin failed to affect the frequency and severity of the toxic effects of multidrug therapy. The immediate and long-term results of the proposed regimen were better than those of the standard one. Complete regressions were 53.3±9.1 and 26.7±8.1, respectively (p = 0.049; Mann—Whitney U-test). Organ-preserving surgery was made in 24 (80.0%) study-group patients and in 16 (53.3%) control ones; the difference being significant (p = 0.03, χ2). In the study group, cumulative survival was significantly higher than that in the control group (p = 0.02, log-rank-test). In the groups, overall 5-year survival was 81.4±7.6 and 46.5±12.5%, respectively.

1. Злокачественные новообразования в Беларуси 1995—2004. А.А. Гракович, И.В. Залуцкий (ред.). Минск, БелЦМТ; 2005.Злокачественные новообразования в Беларуси 1995—2004. А.А. Гракович, И.В. Залуцкий (ред.). Минск, БелЦМТ; 2005.2. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., Вердана; 2001.Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., Вердана; 2001.3. Hautmann R.E., De Petriconi R., Gottfried H.W. et al. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 1999;161(2):422—8.Hautmann R.E., De Petriconi R., Gottfried H.W. et al. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 1999;161(2):422—8.4. Мавричев А.С., Красный С.А., Поляков С.Л. и др. Онкоурология. Минск, БелЦНМИ; 2001.Мавричев А.С., Красный С.А., Поляков С.Л. и др. Онкоурология. Минск, БелЦНМИ; 2001.5. Sell A., Jakobsen A., Nerstrom B. et al. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 1991;138:193—201.Sell A., Jakobsen A., Nerstrom B. et al. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl 1991;138:193—201.6. Матвеев Б.П., Фигурин К.М. Урол и нефрол 1997;(2):25—8.Матвеев Б.П., Фигурин К.М. Урол и нефрол 1997;(2):25—8.7. Митряев Ю.И. Уретеросигмостомия после радикальной цистэктомии в комбинированном лечении рака мочевого пузыря (клинико-экспериментальное исследование). Автореф. дис. … докт. мед. наук. М., 1996.Митряев Ю.И. Уретеросигмостомия после радикальной цистэктомии в комбинированном лечении рака мочевого пузыря (клинико-экспериментальное исследование). Автореф. дис. … докт. мед. наук. М., 1996.8. Ткачук В.Н., Комяков Б.К., Новиков А.И. и др. Рак мочевого пузыря. Материалы конференции 21—22 мая 1998 г., Ростов-на-Дону. с. 91—2.Ткачук В.Н., Комяков Б.К., Новиков А.И. и др. Рак мочевого пузыря. Материалы конференции 21—22 мая 1998 г., Ростов-на-Дону. с. 91—2.9. Amiing C.L, Thrasher J.B., Frazier H.A. et al. J Urol 1994;151(1):31—6.Amiing C.L, Thrasher J.B., Frazier H.A. et al. J Urol 1994;151(1):31—6.10. Морозов А.В., Антонов М.И., Павленко К.А. Урол и нефрол 2000;(3):17—22.Морозов А.В., Антонов М.И., Павленко К.А. Урол и нефрол 2000;(3):17—22.11. Elmajian D.A., Stein J.R, Esrig D., Freeman J.A. et al. J Urol 1996;156(3):920—5.Elmajian D.A., Stein J.R, Esrig D., Freeman J.A. et al. J Urol 1996;156(3):920—5.12. Gburek B.M., Lieber M.M., Blute M.L. Comparison of studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications. J Urol 1998;160(3 Pt 1):721—3.Gburek B.M., Lieber M.M., Blute M.L. Comparison of studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications. J Urol 1998;160(3 Pt 1):721—3.13. Studer U.E., Danuser H., Merz V.W. et al. Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol 1995;154(1):49—56.Studer U.E., Danuser H., Merz V.W. et al. Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol 1995;154(1):49—56.14. Sternberg C.N., Pansadoro V., Calabro F. et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 1999;10(11):1301—5.Sternberg C.N., Pansadoro V., Calabro F. et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol 1999;10(11):1301—5.15. Tester W., Caplan R., Heaney J. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14(1):119—26.Tester W., Caplan R., Heaney J. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14(1):119—26.16. Tester W., Porter A., Asbell S. et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85- 12. Int J Radiat Oncol Biol Phys 1993;25:783—90.Tester W., Porter A., Asbell S. et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85- 12. Int J Radiat Oncol Biol Phys 1993;25:783—90.17. Orsatti M., Curotto A., Canobbio L. et al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995;33(1):173—8.Orsatti M., Curotto A., Canobbio L. et al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys 1995;33(1):173—8.18. Алексеев Б.Я. Внутрипузырная иммунотерапия поверхностного рака мочевого пузыря. Автореф. дис. … канд. мед. наук. М., 1998.Алексеев Б.Я. Внутрипузырная иммунотерапия поверхностного рака мочевого пузыря. Автореф. дис. … канд. мед. наук. М., 1998.19. Фигурин К.М. Химиотерапия и иммунотерапия рака мочевого пузыря. Автореф. дис. … докт. мед. наук. М., 1993.Фигурин К.М. Химиотерапия и иммунотерапия рака мочевого пузыря. Автореф. дис. … докт. мед. наук. М., 1993.20. Pizza G., Berton F., Casanova S. et al. Interleukin-2 in the treatment of infiltrating bladder cancer.J Exp Pathol 1987;3(4):525—31.Pizza G., Berton F., Casanova S. et al. Interleukin-2 in the treatment of infiltrating bladder cancer.J Exp Pathol 1987;3(4):525—31.21. de Reijke T.M., de Boer E.C. Kurth K.H., Schamhart D.H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996;155(2):477—82.de Reijke T.M., de Boer E.C. Kurth K.H., Schamhart D.H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996;155(2):477—82.22. Scher H., Herr H.W., Sternberg C. et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br J Urol 1989;64(3):250—6.Scher H., Herr H.W., Sternberg C. et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br J Urol 1989;64(3):250—6.23. Lynch W.J., Jenkins B.J., Fowler C.G. The quality of life after radical radiotherapy for bladder cancer. Br J Urol 1992;70(5):519—21.Lynch W.J., Jenkins B.J., Fowler C.G. The quality of life after radical radiotherapy for bladder cancer. Br J Urol 1992;70(5):519—21.24. Farah R., Chodak G.W., Vogelzang N.J. et al. Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys 1991;20(3):413—7.Farah R., Chodak G.W., Vogelzang N.J. et al. Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report). Int J Radiat Oncol Biol Phys 1991;20(3):413—7.25. Shearer R.J., Chilvers C.E., Bloom H.J. et al. Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br J Urol 1988;62(6):558—64.Shearer R.J., Chilvers C.E., Bloom H.J. et al. Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br J Urol 1988;62(6):558—64.26. Hall R.R., Newling D.V., Ramsden P.D. et al. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984;56(6):668—72.Hall R.R., Newling D.V., Ramsden P.D. et al. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984;56(6):668—72.27. Kaufman D.S., Shipley W.U., Griffin P.P. et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329(19):1377—82.Kaufman D.S., Shipley W.U., Griffin P.P. et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329(19):1377—82.28. Sauer R., Birkenhake S., Kuhn R. et al. In: Carcinoma of the Bladder. Z. Petrovich, L. Baert, L.W. Brady (eds). Berlin, Springer-Verlag; 1998. p. 205—14.Sauer R., Birkenhake S., Kuhn R. et al. In: Carcinoma of the Bladder. Z. Petrovich, L. Baert, L.W. Brady (eds). Berlin, Springer-Verlag; 1998. p. 205—14.29. Красный С.А., Суконко О.Г., Поляков С.Л., Волков А.Н., Ролевич А.И., Мохорт А.А. Здравоохранение 2004;(5):37—42.Красный С.А., Суконко О.Г., Поляков С.Л., Волков А.Н., Ролевич А.И., Мохорт А.А. Здравоохранение 2004;(5):37—42.